Skip to main content

Tessier-Lavigne Marc's Form 4 filing

Regeneron Pharmaceuticals, Inc. (REGN) · filed Mar 18, 2022

Accession no.
0001708138-22-000020
Filed
Mar 18, 2022
Trade date
Mar 16-17, 2022
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $8.27M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Tessier-Lavigne MarcCIK 0001437435Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 16, 2022Common StockMOption exerciseAcquired+4,361$374.12+$1,631,537.326,630Direct
Mar 16, 2022Common StockSSaleDisposed−4,361$675.00−$2,943,6752,269Direct
Mar 17, 2022Common StockMOption exerciseAcquired+7,830$376.69+$2,949,482.710,099Direct
Mar 17, 2022Common StockSSaleDisposed−7,830$680.00−$5,324,4002,269Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Mar 16, 2022Common StockMOption exerciseDisposed−4,361$0.00$00Direct
Mar 17, 2022Common StockMOption exerciseDisposed−7,830$0.00$00Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Read the full filing on SEC EDGAR (opens in a new tab)